C4 Therapeutics Doses First Patient in Trial

C4 Therapeutics has announced the first patient has been dosed in its Phase 1b trial for Cemsidomide in combination with Elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma. This novel combination regimen is being investigated to potentially position Cemsidomide for use in earlier lines of therapy. The initiation of this trial marks a significant step in evaluating the efficacy and safety of this combined treatment approach for patients with multiple myeloma.